Format

Send to

Choose Destination
Neurology. 2007 Feb 27;68(9):688-90.

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

Author information

1
Department of Neurology, District Medical Center, University of Regensburg, Regensburg, Germany. peter.hau@medbo.de

Abstract

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center